Citations and methodology

Sources behind every number.

Where each statistic on the Qiri site comes from, and the caveat that limits how we use it. Most trace to a peer-reviewed paper, a government dataset or an international body. Where one is a media release, industry modelling or a market report, its entry says so. Where we publish our own modelling, the per-site projections, we list the inputs and assumptions. If a number doesn't add up, tell us.

Jump to: Australia United States New Zealand Global Regulatory Methodology

Australia

Backs the four problem-section statistics on qiri.ai/au, and the scope-of-practice figures in the Australian seed deck.

  1. Felisberto M, et al. Override rate of drug-drug interaction alerts in clinical decision support systems: a systematic review and meta-analysis. Health Informatics J. 2024;30(2). journals.sagepub.com/doi/10.1177/14604582241263242
  2. Johnston K, O'Reilly CL, Scholz B, Georgousopoulou EN, Mitchell I. Burnout and the challenges facing pharmacists during COVID-19: results of a national survey. Int J Clin Pharm. 2021;43(3):716–25. link.springer.com/article/10.1007/s11096-021-01268-5
  3. Lim R, Kalisch Ellett LM, Semple S, Roughead EE. The Extent of Medication-Related Hospital Admissions in Australia: A Review from 1988 to 2021. Drug Saf. 2022;45(3):249–57. link.springer.com/article/10.1007/s40264-021-01144-1
  4. Australian Bureau of Statistics. Regional Population, 2023–24 financial year. Cat. no. 3218.0. abs.gov.au/statistics/people/population/regional-population/latest-release
  5. Premier of Victoria. Making It Easier For Victorians To Get Care At The Chemist. Media release, 19 December 2025. Source for the $18 million Victorian Budget 2025/26 investment, and for “more than 66,000 services at more than 800 pharmacies across Victoria since the pilot began”. Both figures are as at that date. premier.vic.gov.au/making-it-easier-victorians-get-care-chemist
  6. Victorian Department of Health. Community Pharmacist Program. Updated 20 August 2026. Current source for the condition count: the program is “expanding to a total of 23 common health conditions and well-being services”, phased across 2026. The count is a target being reached in stages, not a list available on any one day. health.vic.gov.au/primary-care/community-pharmacist-program
  7. The Pharmacy Guild of Australia (Victoria Branch). Pharmacy Guild welcomes nation-leading $18 million investment in community pharmacies. 20 May 2025. The only source for Victoria being “the only State or Territory where there is no out-of-pocket cost for patients to visit a community pharmacy for a consultation for these expanded healthcare services”. The consultation is free; the medicine is not PBS-subsidised under the program and the patient pays the full medication cost. guild.org.au/news-events/news/vic
  8. HTANALYSTS. Rewriting the Script. Commissioned by The Pharmacy Guild of Australia, released 9 June 2026. National modelling: $1 billion in annual health system savings, more than 10 million GP appointments freed, 30,000 hospitalisations prevented a year, and $21 billion in economic impact across four conditions. Modelled projections of a future state commissioned by an industry body, not observed delivery. Cite it as the Guild’s modelling and never alongside measured figures without that label. guild.org.au/news-events/news/2026
  9. Bupa. Bupa Pulse Check 2025. Media release, 28 April 2025. “7 in 10 employed Australians experienced burnout”, with heavy workload, poor work-life balance and lack of resources the main drivers. Survey of 2,000 Australians by Quantum Market Research with Bupa. All employed Australians, not healthcare and not pharmacists. The release gives no ranking by occupation, so it cannot support any claim that one profession is worse affected than another. media.bupa.com.au/aussies-quality-of-life-improves-for-the-first-time-in-three-years
  10. Dee J, Dhuhaibawi N, Hayden JC. A systematic review and pooled prevalence of burnout in pharmacists. Int J Clin Pharm. 2023;45(5):1027–1036. 19 articles, 11,306 pharmacists, eight countries: “More than half (51%) of pharmacists were experiencing burnout.” This is the source for the 1 in 2 figure on qiri.ai/au. Pooled across eight countries, so it is not an Australian prevalence and the figure is never written as “Australian pharmacists”. No Australian pharmacist burnout prevalence has been published; Johnston 2021 (au-2) is Australian but reports mean MBI subscale scores rather than a prevalence. link.springer.com/article/10.1007/s11096-022-01520-6
  11. Pharmaceutical Society of Australia. Safe and quality use of medicines the focus of new parliamentary friendship group. Media release, 19 August 2026, on the launch of the Parliamentary Friends of Safe and Quality Use of Medicines. “Around 650,000 hospital and emergency department visits every year”, at a cost of “$2.1 billion annually”, around half of them avoidable. psa.org.au. Hospital and emergency visits together. About 250,000 are admissions and 400,000 emergency presentations. The harm is not attributed to community pharmacists.

United States

Backs the four problem-section statistics on qiri.ai/us, plus the workforce figure cited on /1995.

  1. Felisberto M, et al. Override rate of drug-drug interaction alerts in clinical decision support systems: a systematic review and meta-analysis. Health Informatics J. 2024;30(2). journals.sagepub.com/doi/10.1177/14604582241263242
  2. Kisala JR, et al. Evaluation of the Current State of Burnout Among Clinical Pharmacists. J Am Coll Clin Pharm. 2025. Supporting only. The population is clinical pharmacists, so it does not back the community-pharmacy burnout figure on qiri.ai/us, which uses the Mayo Well-Being Index below. accpjournals.onlinelibrary.wiley.com/doi/10.1002/jac5.70139
  3. Watanabe JH, McInnis T, Hirsch JD. Cost of Prescription Drug-Related Morbidity and Mortality. Ann Pharmacother. 2018;52(9):829–37. journals.sagepub.com/doi/10.1177/1060028018765159
  4. Guadamuz JS, Alexander GC, Chaudhri T, Trotzky-Sirr R, Qato DM. Locations and characteristics of pharmacy deserts in the United States: a geospatial study. Health Affairs Scholar. 2024;2(4):qxae035. academic.oup.com/healthaffairsscholar/article/2/4/qxae035
  5. Mayo Clinic Well-Being Index. State of Well-Being report, 2022–2023. 2023 data, 79,022 assessments: pharmacy professionals 62%, nurses 52%, physicians 51%. mywellbeingindex.org/downloads/state-of-well-being-2022-2023-report

Global

Backs the four problem-section statistics on qiri.ai/global.

  1. Felisberto M, et al. Override rate of drug-drug interaction alerts in clinical decision support systems: a systematic review and meta-analysis. Health Informatics J. 2024;30(2). journals.sagepub.com/doi/10.1177/14604582241263242
  2. Dee J, Dhuhaibawi N, Hayden JC. A systematic review and pooled prevalence of burnout in pharmacists. Int J Clin Pharm. 2023;45(5):1027–1036. link.springer.com/article/10.1007/s11096-022-01520-6
  3. World Health Organization. WHO launches global effort to halve medication-related errors in 5 years. News release, 29 March 2017, launching the Third Global Patient Safety Challenge, Medication Without Harm. The cost of medication errors “has been estimated at US$ 42 billion annually”, almost 1% of global health spending. who.int. The challenge itself: Donaldson LJ, Kelley ET, Dhingra-Kumar N, Kieny MP, Sheikh A. Medication Without Harm: WHO's Third Global Patient Safety Challenge. The Lancet. 2017;389(10080):1680–1681. An estimate, in US dollars.
  4. World Health Organization. Ten years in public health 2007–2017. Geneva: WHO; 2017. “An estimated two billion people have no access to essential medicines.” who.int. A long-standing WHO estimate, not re-measured since.

Regulatory frameworks

Backs the regulatory pathway on qiri.ai/trust. Qiri Phase 1 is designed against these frameworks, and we claim no approval we have not obtained.

  1. US Food and Drug Administration. Clinical Decision Support Software, Final Guidance. January 2026. Defines the four Non-Device CDS criteria under FD&C Act §520(o)(1)(E): no medical-image/signal analysis; displays patient medical information; provides recommendations to a healthcare professional; enables the HCP to independently review the basis. Qiri Phase 1 is architected against all four. fda.gov/regulatory-information/search-fda-guidance-documents/clinical-decision-support-software
  2. Australian Therapeutic Goods Administration. Regulation of software-based medical devices. Technology-agnostic SaMD framework, which regulates software by its intended purpose rather than the technology it uses. tga.gov.au/products/medical-devices/software-based-medical-devices
  3. Commonwealth of Australia. Therapeutic Goods Legislation Amendment (2026 Measures No. 1) Regulations 2026, Part 3, amending item 2.15 of Schedule 4 to the Therapeutic Goods (Medical Devices) Regulations 2002. In force from 1 November 2026, including for software made earlier and used after that date. Clinical decision support software stays exempt from ARTG inclusion when it recommends to a health professional, does not analyse medical images or signals, does not replace or make the clinical diagnosis or treatment decision, and displays the guidelines, calculations or logic behind each recommendation so the professional can readily interpret and verify it. The TGA states the amendments clarify the exemption and do not change its scope. Qiri Phase 1 in Australia is designed against all five conditions. legislation.gov.au/F2026L01167
  4. European Union. Regulation (EU) 2024/1689, the Artificial Intelligence Act. Adopted June 2024; staged into force 2026–2027. Risk-classification framework for AI in healthcare. Qiri's pharmacist-in-the-loop and reasoning trace are designed against high-risk obligations: human oversight, transparency, record-keeping. eur-lex.europa.eu/eli/reg/2024/1689/oj
  5. Pharmacy Board of Australia (AHPRA). Code of conduct and Guidelines on dispensing of medicines. Defines the professional and legal standard for pharmacist oversight of dispensing in Australia, including the pharmacist's independent responsibility for clinical appropriateness, counselling, and final dispensing decisions. Qiri's pharmacist-in-the-loop architecture is designed so the pharmacist remains the regulated decision-maker under these standards. Qiri provides reasoning, the pharmacist provides the professional judgment the Code requires. pharmacyboard.gov.au/codes-guidelines.aspx

Methodology for per-site projections

The per-site model behind the return-on-intelligence figures, worked separately for each market.

The return-on-intelligence figures on the locale pages come from a Qiri internal model built on public benchmarks, not from external literature. Australia and the United States are modelled separately, with different script volumes, different loaded wage rates, different currency, and only Australia carries funded clinical services. The two headline dollar figures are therefore built differently and should not be read against each other. The model is instrumented in live pilots now, and these figures are updated as pilot readouts land.

Inputs and arithmetic:

Input
Value
Basis
Script volume
AU ~200 a trading day, modelled
US ~250 dispenses a day, modelled
Both are modelling assumptions, not published averages. In Australia, for scale, 328.2M subsidised and under-co-payment prescriptions (FY2024–25) across about 5,900 community pharmacies is about 185 a trading day, per the PBS Expenditure and Prescriptions Report, 2024–25, Table 2(a). Prescriptions fell 1.3% on the prior year, which the same table restates as 332.5M. The report does not separate community pharmacy from other PBS dispensing, so the true community-pharmacy figure sits below 185, not above it. In the US there is no sourced scripts-per-day figure we are willing to publish, so we do not state one.
Time recovered per script
45–60 seconds
The model's only time assumption, and the same in both markets. Held deliberately below observational estimates of routine verification time (3–5 minutes per script).
Hours recovered
AU 750–1,000 a year
US 938–1,250 a year
Scripts × 45–60 seconds × ~300 trading days. That is 2.5–3.3 hours a day in Australia and 3.1–4.2 in the US. The locale pages round both bands down, to 2–3 and 3–4 hours.
Pharmacist loaded hourly rate
AU A$60–90
US US$65–85
Base salary plus ~25–30% on-costs (superannuation or benefits, leave loading, employer payroll obligations). AU from the Fair Work Pharmacy Industry Award (MA000012) base plus on-costs; US from BLS Pharmacists, Occupational Employment Statistics. The per-site model uses each pharmacy's actual loaded rate at deployment.
Wage value recovered
AU A$45–90K
US US$61–106K
Hours recovered × the loaded rate, at both ends of each band.
Funded services capacity
AU only, ~A$30K a year at the cap
Australian only. Recovered time can be redirected into funded clinical services, and MedsCheck alone is capped at 20 services per pharmacy per month under the Pharmacy Programs Administrator. The US model claims no equivalent, because US reimbursement for pharmacist clinical services varies by state and payer and we have not modelled it.
Headline value per site
AU A$75–90K
US US$60–100K
The two figures are built differently and are not comparable. AU combines the conservative half of the wage band with partial use of funded services capacity. US is wage value only, rounded down from A$61–106K.
Indemnity
100% of decisions documented
Inputs, sources cited, rules fired, model used, pharmacist action, outcome. We do not publish a claims-reduction percentage. The effect on premiums and claims is being assessed with pilots and insurers, and until then the audit trail itself is the claim.
Validation
Live pilots, now
Pilots instrument time recovered per script and alert precision per site. Figures on this page are updated as pilot readouts land.

Market sizing (investor materials): global pharmacy management software and services is US$116.5B in 2026, growing to US$236.3B by 2031 at 15.2% CAGR, per Mordor Intelligence (July 2026), corroborated by The Business Research Company and 360iResearch; conservative scopes size the same category at US$34–53B. Clinical decision support software, the category Qiri’s reasoning layer competes in, reaches US$6.49B by 2030 at 13.1% CAGR across all care settings, per The Business Research Company (September 2026). For comparison, Heidi, the Melbourne-built AI scribe, raised US$340M (a US$100M Series C led by Blackbird plus US$240M of growth capital) at a US$900M valuation, reporting 2.8 million patient visits a week and ARR of US$50M as at April 2026, per its announcement of 22 September 2026. Dispensing labour: US pharmacies employ 321,970 pharmacists (mean wage US$140,920) and 471,680 pharmacy technicians (mean US$46,620), a combined wage bill of roughly US$67B a year, per BLS OEWS May 2025, occupation 29-1051 and 29-2052.

Ask Qiri

Backs the general-chatbot statistics on qiri.ai/ask-qiri. These figures describe general-purpose chatbots and AI search assistants, not purpose-built clinical software.

  1. Grossman S, Zerilli T, Nathan JP. Appropriateness of ChatGPT as a resource for medication-related questions. Br J Clin Pharmacol. 2024;90(10):2691–2695. doi:10.1111/bcp.16212. Long Island University College of Pharmacy put 39 real questions from its drug information service (2022 to 2023) to free ChatGPT. 29 of 39 (74%) were not answered satisfactorily on pharmacist review: no direct answer, inaccurate, incomplete or not relevant. Eight answers cited references, and every one of those included references that do not exist.
  2. Andrikyan W, et al. Artificial intelligence-powered chatbots in search engines: a cross-sectional study on the quality and risks of drug information for patients. BMJ Qual Saf. 2025;34(2):100–109. doi:10.1136/bmjqs-2024-017476. Bing Copilot answered 500 patient questions on the 50 most-used US medicines in April 2023. Experts reviewed a subset of 20 answers picked for low accuracy, low completeness or likely risk. Of those, 66% were judged potentially harmful, 22% could have caused severe harm or death, 54% aligned with scientific consensus and 39% contradicted it. The 20 were picked as weak. Across all 500 answers, median accuracy and completeness were 100%.

New Zealand

Backs the New Zealand framing on qiri.ai/nz. Its problem statistics are the global figures above, labelled as global, except the pharmacist wellbeing figure, which is New Zealand's own (nz-4).

  1. Health New Zealand | Te Whatu Ora. New Zealand ePrescription Service (NZePS). The national prescription broker, run by Health New Zealand. Backs the NZePS references on qiri.ai/nz; Qiri's integration is in progress and is not claimed as complete. healthnz.govt.nz/health-professionals/guidance-standards/topic/medicines-prescriptions/new-zealand-eprescription-service-nzeps
  2. Pharmacy Council of New Zealand. Standards and practice: Competence Standards and the Code of Ethics. Defines the professional standard for pharmacists practising in New Zealand. Qiri's pharmacist-in-the-loop architecture is designed so the registered pharmacist remains the decision-maker. Qiri provides reasoning, the pharmacist provides the professional judgment. pharmacycouncil.org.nz/i-am-a-pharmacist/standards-and-practice
  3. Office of the Privacy Commissioner. Health Information Privacy Code 2020. The rules for collecting, storing, using and disclosing health information in New Zealand, including information held offshore. privacy.org.nz/privacy-principles/codes-of-practice/hipc2020
  4. Pharmaceutical Society of New Zealand. PSNZ Workforce Survey 2024. Survey of PSNZ members, closed 2 July 2024, results released 4 September 2024: two thirds (66%) of community pharmacy respondents said their work had a negative impact on their mental health and wellbeing. 431 members responded. pharmacytoday.co.nz. Self-selected PSNZ members, and a measure of harm to wellbeing, not a burnout scale. No peer-reviewed study has measured burnout across New Zealand pharmacists.
Qiri

Have a number we should add?

If you have peer-reviewed data, regulator publications, or actuarial evidence we should be citing, share it. We update this page when better sources land.